New drug combo tested to shrink aggressive breast cancer before surgery
NCT ID NCT04230109
Summary
This study is testing whether the drug sacituzumab govitecan, alone or combined with pembrolizumab, can shrink tumors before surgery in people with localized triple-negative breast cancer. About 260 participants will receive the study treatment for up to 12 weeks, followed by standard chemotherapy if needed. Researchers want to see if this approach can eliminate cancer from the breast and lymph nodes and improve surgery options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-••••
Contact
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-••••
Contact
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Massachusetts General Hospital - North Shore Cancer Center
RECRUITINGDanvers, Massachusetts, 01923, United States
Contact Phone: •••-•••-••••
Contact
-
Massachusetts General Hospital at Newton-Wellesley Hospital
RECRUITINGNewton, Massachusetts, 02462, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.